S&P 500   3,662.72 (+0.01%)
DOW   29,797.09 (-0.09%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   214.43 (-0.82%)
FB   289.47 (+1.02%)
GOOGL   1,830.55 (+1.96%)
AMZN   3,219.53 (-0.02%)
TSLA   563.25 (-3.68%)
NVDA   544.40 (+1.64%)
BABA   262.27 (-0.66%)
CGC   28.27 (+6.08%)
GE   10.37 (+2.17%)
MU   68.59 (+2.25%)
AMD   94.44 (+1.95%)
T   28.93 (+0.21%)
NIO   46.83 (+3.24%)
F   9.18 (-0.65%)
ACB   10.99 (+12.72%)
NFLX   505.30 (+0.14%)
BA   218.80 (+2.72%)
GILD   61.31 (+0.31%)
DIS   152.60 (+2.11%)
S&P 500   3,662.72 (+0.01%)
DOW   29,797.09 (-0.09%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   214.43 (-0.82%)
FB   289.47 (+1.02%)
GOOGL   1,830.55 (+1.96%)
AMZN   3,219.53 (-0.02%)
TSLA   563.25 (-3.68%)
NVDA   544.40 (+1.64%)
BABA   262.27 (-0.66%)
CGC   28.27 (+6.08%)
GE   10.37 (+2.17%)
MU   68.59 (+2.25%)
AMD   94.44 (+1.95%)
T   28.93 (+0.21%)
NIO   46.83 (+3.24%)
F   9.18 (-0.65%)
ACB   10.99 (+12.72%)
NFLX   505.30 (+0.14%)
BA   218.80 (+2.72%)
GILD   61.31 (+0.31%)
DIS   152.60 (+2.11%)
S&P 500   3,662.72 (+0.01%)
DOW   29,797.09 (-0.09%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   214.43 (-0.82%)
FB   289.47 (+1.02%)
GOOGL   1,830.55 (+1.96%)
AMZN   3,219.53 (-0.02%)
TSLA   563.25 (-3.68%)
NVDA   544.40 (+1.64%)
BABA   262.27 (-0.66%)
CGC   28.27 (+6.08%)
GE   10.37 (+2.17%)
MU   68.59 (+2.25%)
AMD   94.44 (+1.95%)
T   28.93 (+0.21%)
NIO   46.83 (+3.24%)
F   9.18 (-0.65%)
ACB   10.99 (+12.72%)
NFLX   505.30 (+0.14%)
BA   218.80 (+2.72%)
GILD   61.31 (+0.31%)
DIS   152.60 (+2.11%)
S&P 500   3,662.72 (+0.01%)
DOW   29,797.09 (-0.09%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   214.43 (-0.82%)
FB   289.47 (+1.02%)
GOOGL   1,830.55 (+1.96%)
AMZN   3,219.53 (-0.02%)
TSLA   563.25 (-3.68%)
NVDA   544.40 (+1.64%)
BABA   262.27 (-0.66%)
CGC   28.27 (+6.08%)
GE   10.37 (+2.17%)
MU   68.59 (+2.25%)
AMD   94.44 (+1.95%)
T   28.93 (+0.21%)
NIO   46.83 (+3.24%)
F   9.18 (-0.65%)
ACB   10.99 (+12.72%)
NFLX   505.30 (+0.14%)
BA   218.80 (+2.72%)
GILD   61.31 (+0.31%)
DIS   152.60 (+2.11%)
Log in
ARCA:AMPE

Ampio Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.32 million shs
Market Capitalization$159.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone720 437 6500
Employees23

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.06 per share

Profitability

Net Income$-13,630,000.00

Miscellaneous

Market Cap$159.28 million
Next Earnings DateN/A
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive AMPE News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ampio Pharmaceuticals (ARCA:AMPE) Frequently Asked Questions

What stocks does MarketBeat like better than Ampio Pharmaceuticals?

Wall Street analysts have given Ampio Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ampio Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Ampio Pharmaceuticals' key competitors?

Who are Ampio Pharmaceuticals' key executives?

Ampio Pharmaceuticals' management team includes the following people:
  • Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 68, Pay $305k)
  • Mr. Daniel G. Stokely CPA, CPA, CFO, Corp. Sec. & Treasurer (Age 56, Pay $276k)
  • Ms. Holli Cherevka, Chief Operating Officer (Age 37, Pay $278k)
  • Lane Hapke, VP of Manufacturing Operations
  • April Ramirez, Clinical Trial Mang.
  • Laura Goldberg, VP of Quality and Regulatory Operations

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the ARCA under the ticker symbol "AMPE."

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Ampio Pharmaceuticals?

Ampio Pharmaceuticals has a market capitalization of $0.00. The company earns $-13,630,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Ampio Pharmaceuticals employs 23 workers across the globe.

What is Ampio Pharmaceuticals' official website?

The official website for Ampio Pharmaceuticals is www.ampiopharma.com.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 INVERNESS PARKWAY SUITE 200, ENGLEWOOD CO, 80112. The company can be reached via phone at 720 437 6500.

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.